Kenvue Inc.(KVUE)
Kenvue Inc. operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, and other products under the Tylenol, Nicorette, and Zyrtec brands. The Skin Health and Beauty segment provides face and body care, hair care, and sun and other care products under the Neutrogena, Aveeno, and OGX brand names. The Essential Health segment offers oral and baby, women's health, and wound care products under the Listerine, Johnson's, Band-Aid, and Stayfree brands. The company was incorporated in 2022 and is headquartered in Skillman, New Jersey. Kenvue Inc. operates as a subsidiary of Johnson & Johnson.
Latest News & Analysis
Kenvue's 2025 Outlook: Challenges and Turnaround Strategies
A deep-dive analysis of Kenvue's Q4 2024 performance, 2025 outlook, cost-cutting initiatives, and brand turnaround measures.
Kenvue's 2025 Turnaround: Cost Cuts & Brand Revival
A comprehensive intraday analysis of Kenvue's performance, strategy, and market position as of February 20, 2025, focusing on data-driven insights and key developments.
Kenvue News Update (Failed Generation)
Content generation failed - Recovery needed
Kenvue's Post-Spin-Off Strategy: Challenges & Growth
A detailed analysis of KVUE’s post-spin-off performance, dividend sustainability, cost-cutting initiatives, and market trends in 2025.
Kenvue Inc. (KVUE): Strategic Analysis, Financial Performance, and Future Outlook
A comprehensive analysis of Kenvue Inc. (KVUE), examining its CAGNY conference presentation, Starboard Value's impact, Q4 2024 earnings, and future outlook.
Kenvue Inc. (KVUE): Market Analysis, Challenges, and Future Outlook
A comprehensive analysis of Kenvue Inc.'s market position, challenges, and future prospects, focusing on strategic shifts, dividend sustainability, and market dynamics.
Kenvue Inc. Financial Analysis: Strategic Shifts and Cost-Cutting Insights
A detailed data-driven analysis of Kenvue Inc.'s cost-saving initiatives, board changes, financial performance, and competitive market dynamics.
Kenvue: Clinical Data, Governance Changes, and Financial Outlook
Analysis of Kenvue's clinical data, governance changes with Starboard, dividend sustainability, and recession resilience, providing a comprehensive overview of its position and prospects.
Kenvue (KVUE): Navigating Market Volatility, Board Changes, and Dividend Dilemmas
Analysis of Kenvue's (KVUE) board changes, skin health strategy, recession risks, and dividend sustainability. Includes valuation metrics and clinical data insights.
Kenvue (KVUE) Analysis: New Headquarters, Starboard, Financials
Analysis of Kenvue's strategic shifts, new headquarters, Starboard Value's influence, and financial outlook. Key insights into growth, health, and economic resilience.
Kenvue (KVUE): Strategic Growth, Dividend Sustainability, and Market Resilience
Kenvue Inc. navigates the consumer healthcare market with strategic moves, innovation, and activist investor engagement. Dividend sustainability and market resilience are key focuses.
Kenvue's Strategic Overhaul: Navigating Growth Challenges
A deep dive into Kenvue's strategic moves, financial health, and market challenges. Discover how 'Extraordinary Powers' and celebrity endorsements aim to drive growth.
Kenvue (KVUE) Financial Analysis: Dividend, AI Strategy, and Profitability Challenges
Kenvue (KVUE) faces challenges with declining profitability and cash flow despite strategic moves and dividend commitments. Analyst expectations point to a potential recovery.
Kenvue (KVUE) Analysis: Fortune 500 Debut & Strategic Focus
Kenvue Inc. debuts on the Fortune 500 list, navigating macroeconomic headwinds with strategic cost-saving initiatives and leveraging its strong brand portfolio.
Kenvue's Strategic Divestitures & Legal Challenges Analysis
Kenvue's Fortune 500 debut is overshadowed by strategic brand divestitures and legal scrutiny. Dive into Q1 results, strategic shifts, and market impact.
Kenvue Inc.: Strategic Divestitures and M&A Dynamics Analysis
Kenvue Inc. faces pivotal moments with M&A speculation, portfolio divestitures, and ongoing legal challenges shaping its future valuation and market position.
Kenvue's Strategic Pivot: Debt Management, Portfolio Refocus, and M&A Dynamics
Kenvue's future hinges on its August 2025 J&J tax agreement expiration and strategic brand divestitures amid declining net income and high dividend payout.
Kenvue Inc. Market Analysis: Strategic M&A Window, Financial Health & Dividend Sustainability
Explore Kenvue Inc.'s critical August M&A window, brand portfolio optimization, financial performance, and dividend sustainability shaping investor outlook in 2025.
Kenvue Inc. Strategic Review and Leadership Shift Amid Q2 Sales Decline | Monexa AI
Kenvue faces Q2 2025 sales decline leading to CEO transition and strategic review focused on portfolio optimization and operational efficiency.
Kenvue Inc. (KVUE) Financial Analysis: Profitability Dip Amidst Milestones
Kenvue Inc. navigates legal challenges and profitability shifts while celebrating its Fortune 500 debut. An in-depth look at recent financials and strategic moves.
Kenvue Inc. Strategic Review and Leadership Shift Impact Financial Outlook - Monexa AI
Kenvue faces strategic crossroads with CEO change and Q2 sales warning amid evolving consumer health market dynamics.
Kenvue Inc. Leadership Shift and Strategic Review Impact Financial Metrics | Monexa AI
Kenvue Inc. faces a pivotal leadership change and strategic review amid Q2 sales decline and dividend sustainability concerns, shaping its financial outlook.
Kenvue Inc. Strategic Review and Leadership Overhaul Impact on Financials and Market Position
Kenvue Inc. undertakes a strategic review with leadership changes, focusing on portfolio optimization, Q2 2025 earnings, and dividend sustainability.
Kenvue Inc. Q2 2025 Analysis: Strategic Review Amid Earnings Miss and Leadership Changes
Kenvue's Q2 2025 earnings reveal sales declines and profit forecast cuts amid leadership shifts and strategic portfolio review, impacting growth outlook.
Kenvue Inc.: Earnings Shock, Activist Drive and Capital‑Allocation Strain
Kenvue's FY2024 net income plunged to **$1.03B** (-37.95% YoY) while activists press for a strategic review as the company trades at **$21.31** with a **3.86%** yield.
Kenvue Inc. (KVUE): Earnings, Dividends and the Risk Profile After FY2024 Slippage
Kenvue's FY2024 saw **net income drop -38.0%** and **free cash flow fall -50.7%** while the company kept a **$0.8225** annual dividend, leaving payout above 100%.